# Financial toxicity and financial navigation

Source: https://onco.cc/technologies/financial-navigation/  
OnCo record `financial-navigation` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cancer treatment can bankrupt patients even with insurance. Financial navigation programmes screen for money problems and connect patients to assistance, insurance optimisation and legal help, and trials show they reduce distress and debt.

## Summary

'Financial toxicity' (Zafar 2013) describes the material, psychological and behavioural harm of cancer costs: ~40% of US patients deplete savings within two years (Gilligan 2018) and cancer patients are 2.65 times more likely to declare bankruptcy, which itself predicts mortality (Ramsey 2016). Drivers: high drug prices, cost-sharing, lost income, travel. Measurement: COST-FACIT. Interventions: proactive screening, financial navigators/counsellors (Lentz, Banegas), pharmaceutical assistance programmes, medication cost conversations, and policy (Inflation Reduction Act cap on Part D out-of-pocket costs from 2025; Medicaid expansion). Randomised and pragmatic trials (CAFÉ, 2024) show reduced financial distress and increased assistance uptake. Globally, catastrophic expenditure affects most cancer households in LMICs (ACTION study, Southeast Asia).

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-08
- Tags: gap-fill; supportive; equity
- Principle: Treat cost as a side effect: screen routinely, quantify with validated tools, and assign trained staff to reduce out-of-pocket exposure through benefits, assistance programmes and treatment choices with equal efficacy and lower cost.
- Since: 2013
- Strengths: Trials show reduced distress and recovered funds far exceeding programme cost; Aligns with value-based care metrics; Highlights price as a modifiable harm
- Limitations: Does not address root cause (drug and service prices); Programmes concentrated in large centres; LMIC household costs are largely unaddressed

## Notes

- Lung cancer in the UK: Cancer Research UK lists money matters, benefits, sick pay, prescription costs and grants, work issues, early retirement, childcare, Blue Badge applications, help with travel costs and changes to the house among the practical things people need help with, says a hospital social worker can help, and says getting help early stops these becoming a bigger issue later. Roy Castle has sections on working with lung cancer and employment rights, financial support, and travel and travel insurance.

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Financial_toxicity
- Gilligan 2018 (Am J Med): https://doi.org/10.1016/j.amjmed.2018.05.020
- Ramsey 2016 bankruptcy and survival (JCO): https://doi.org/10.1200/JCO.2015.64.6620
- Roy Castle Lung Cancer Foundation: living with lung cancer: https://roycastle.org/learn-about-lung-cancer/living-with-cancer/
- Cancer Research UK: coping and support when you have lung cancer: https://www.cancerresearchuk.org/about-cancer/lung-cancer/living-with/coping

## Connected records

- cancers: [Advanced-stage classical Hodgkin lymphoma (stage III to IV)](https://onco.cc/cancers/advanced-stage-classical-hodgkin-lymphoma/), [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Early-stage classical Hodgkin lymphoma (stage I to II)](https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Marginal zone lymphoma](https://onco.cc/cancers/marginal-zone-lymphoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)](https://onco.cc/cancers/peripheral-t-cell-lymphoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Relapsed and refractory classical Hodgkin lymphoma](https://onco.cc/cancers/relapsed-refractory-hodgkin-lymphoma/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- fronts: [Recovery & Rejuvenation](https://onco.cc/fronts/rejuvenation/), [Supportive Care & Survivorship](https://onco.cc/fronts/supportive-care/)
- technologies: [After treatment in the United States: the survivorship care plan, and what the trial found](https://onco.cc/technologies/rejuv-access-survivorship-care-us/), [Employment rights with cancer in the United States](https://onco.cc/technologies/rejuv-life-employment-rights-us/), [EQ-5D: health reduced to one number, and what that number is for](https://onco.cc/technologies/rejuv-measure-eq-5d/), [Insurance, mortgages and the right to be forgotten](https://onco.cc/technologies/rejuv-life-insurance-loans-and-the-right-to-be-forgotten/), [Money after treatment: what the cost of cancer does once the treatment has finished](https://onco.cc/technologies/rejuv-life-money-after-treatment/), [Screening for distress: what the thermometer can and cannot do](https://onco.cc/technologies/rejuv-mind-distress-screening/), [Survivorship care and late-effects surveillance](https://onco.cc/technologies/survivorship-care-plan/), [Telehealth and hospital-at-home in oncology](https://onco.cc/technologies/telehealth-oncology/), [The devices that do the restoring, and who pays for them](https://onco.cc/technologies/rejuv-rehab-assistive-devices/), [The gap between the rehabilitation people need and the rehabilitation they are offered](https://onco.cc/technologies/rejuv-rehab-provision-gap/), [What recovery costs in the rest of the world](https://onco.cc/technologies/rejuv-access-what-it-costs-elsewhere/), [What recovery costs in the UK, and what it does not](https://onco.cc/technologies/rejuv-access-what-it-costs-uk/), [What recovery costs in the United States](https://onco.cc/technologies/rejuv-access-what-it-costs-us/), [Where rehabilitation is commissioned, and who misses out](https://onco.cc/technologies/rejuv-rehab-commissioning-inequity/), [Who misses out on recovery care, measured](https://onco.cc/technologies/rejuv-access-who-misses-out/)
- companies: [Patient Advocators](https://onco.cc/companies/patient-advocators/), [TailorMed](https://onco.cc/companies/tailormed/)
- terms: [Cancer health disparities and equity](https://onco.cc/terms/cancer-health-disparities/), [Financial toxicity](https://onco.cc/terms/financial-toxicity/), [Going back to work after lymphoma, and the money in the meantime](https://onco.cc/terms/lymphoma-living-returning-to-work/), [Oncology drug pricing and price transparency](https://onco.cc/terms/drug-price-transparency/), [Treatment at the local hospital or at a cell-therapy centre far from home](https://onco.cc/terms/lymphoma-decision-local-or-car-t-centre/)
- key papers: [Death or Debt? National Estimates of Financial Toxicity in Persons with Newly-Diagnosed Cancer](https://onco.cc/key-papers/paper-gilligan-am-j-med/), [Financial Insolvency as a Risk Factor for Early Mortality Among Patients With Cancer](https://onco.cc/key-papers/paper-ramsey-j-clin-oncol/)

---
JSON: https://onco.cc/api/v1/entities/financial-navigation.json